-
Infection and Drug Resistance
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Daptomycin: a novel lipopeptide antibiotic against Gram-positive pathogens
Review
(2036) Views (984) Full article downloads
Authors: Andres Beiras-Fernandez, Ferdinand Vogt, Ralf Sodian, et al.
Published Date August 2010
Volume 2010:3 Pages 95 - 101
DOI: http://dx.doi.org/10.2147/IDR.S6961
Andres Beiras-Fernandez1,*, Ferdinand Vogt1,*, Ralf Sodian1, Florian Weis21Department of Cardiac Surgery, University Hospital Großhadern, Ludwig-Maximilian-University, Munich, Germany; 2Department of Anesthesiology, University Hospital Großhadern, Ludwig-Maximilian-University, Munich, Germany *Andres Beiras-Fernandez and Ferdinand Vogt contributed equally to this paper
Abstract: The aim of this review is to summarize the historical background of drug resistance of Gram-positive pathogens as well as to describe in detail the novel lipopeptide antibiotic daptomycin. Pharmacological and pharmacokinetic aspects are reviewed and the current clinical use of daptomycin is presented. Daptomycin seems to be a reliable drug in the treatment of complicated skin and skin structure infections, infective right-sided endocarditis, and bacteremia caused by Gram-positive agents. Its unique mechanism of action and its low resistance profile, together with its rapid bactericidal action make it a favorable alternative to vancomycin in multi-drug resistant cocci. The role of daptomycin in the treatment of prosthetic material infections, osteomyelitis, and urogenital infections needs to be evaluated in randomized clinical trials.
Keywords: daptomycin, multi-drug resistance, methicillin-resistant Staphylococcus aureus (MRSA), pneumonia, urinary tract infection, left-sided endocarditis
Readers of this article also read:
The determinants of the antibiotic resistance process
Anidulafungin and its role in candida infections
Prevention strategies for antimicrobial resistance: a systematic review of the literature
Occult hepatitis B virus infection in Egyptian hemodialysis patients with or without hepatitis C virus infection
Current strategies for the prevention and management of central line-associated bloodstream infections
Boceprevir in the treatment of chronic hepatitis C virus infection
Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients
High prevalence of extended-spectrum β-lactamase-producing pathogens: results of a surveillance study in two hospitals in Ujjain, India
The effects of daily chlorhexidine bathing on cutaneous bacterial isolates: a pilot study
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- Evaluation of in-vitro antibiotic susceptibility of different morphological forms of Borrelia burgdorferi
- Treatment of drug-resistant tuberculosis
- Subset-directed antiviral treatment of 142 herpesvirus patients with chronic fatigue syndrome
- High prevalence of multidrug-resistant MRSA in a tertiary care hospital of northern India




